Navigation Links
DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
Date:3/16/2009

CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of chronic pain. The development program for this drug candidate was reviewed with the U.S. Food and Drug Administration (FDA) during a successful end-of-Phase II meeting with the FDA on February 19, 2009. As a result of that meeting, we believe we understand the anticipated regulatory pathway for the Phase III program and approval, which we expect will follow a 505(b)2 pathway as discussed with FDA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"In this trial, all of the primary and secondary objectives were met by showing patients could be successfully converted from oral opioids such as OxyContin(R) and from fentanyl patches such as Duragesic(R) to TRANSDUR-Sufentanil, while also showing a reduction in pain scores on our therapy," stated James Brown, President and CEO of DURECT Corporation. "We believe that our small, patient-friendly seven day sufentanil patch would compete effectively in the chronic pain market including both patches and oral opioids."

In addition to the recent Phase IIb study, there have been 9 additional clinical studies performed to date with TRANSDUR-Sufentanil that have involved over 300 patient exposures. These studies include evaluating wearing, pharmacokinetics, specialty populations, repeat applications, skin abrasions, drug interactions and dose conversions. In addition, a non-clinical package comprising multiple animal safety studies has been developed, including carcinogenicity studies, long-ter
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... HealthWarehouse.com , Inc. (OTC: HEWA), a leading ... its pre-order program to enable consumers immediate access to Atorvastatin ... offer the medication at up to 50 percent less ... "We will be one of the earliest and ...
... Nov. 29, 2011  In a new study presented today at ... (RSNA), growth hormone replacement for six months was found to ... is the first time that the effects of growth hormone ... lead author, Miriam A. Bredella, M.D., a radiologist at Massachusetts ...
Cached Medicine Technology:HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 2HealthWarehouse.com Offers Lowest Price Generic Lipitor on the Market 3Growth Hormone Increases Bone Formation in Obese Women 2
(Date:12/25/2014)... Carolina (PRWEB) December 25, 2014 ... Carolina Retirement Community, recently showed their generous spirit ... of the Catawba County Parenting Network- Grandparents Raising ... 10 children gathered around the largest Christmas tree ... open presents purchased by residents of the Abernethy ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... 2014 New studies reveal that women under ... related depression (March 6, 2014, JAMA Otolaryngology*). And although many ... (about 50 percent according to recent polls) facing hearing loss ... a person feels and relates to the world. People who ... also made by way of:, , self-confidence ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, has presented ... a site-wide wedding gown promotion. , For those ... more unexpected way, the collection should be a great choice. ... market, and they are available with custom service. , Now, ... prices, up to 75% off; most of them come in ...
Breaking Medicine News(10 mins):Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... HCA today announced financial,and operating results for the third quarter ... increased 5.7 percent to $6.569 billion. -- Adjusted EBITDA totaled ... the prior year. -- Net income totaled $300 million, ... year. -- Interest expense increased to $560 million, up from ...
... in 2008, HOUSTON, Nov. 7 In ... and RediClinic Services units of RediClinic,LLC have been ... have been promoted and two new executives have ... chief operating officer of the RediClinic,division, has been ...
... America, the premier network,of diabetes care and management centers ... its physicians have been recognized by the,Diabetes Physician Recognition ... Dr. Wendy Hawkins M.D., Dr. Damon,Weddington M.D., Dr. Alice ... M.D. were all honored in Houston today. "The ...
... Inc. (Amex:,ADL), with operations in Shenzhen, Jiangxi and ... Inc. (JPI), which is an,international biopharma company that ... pharmaceutical and diagnostic,products, announced today that JPI,s subsidiary ... agreements for its new anti-aging and skin,care injectable ...
... at 8:00 a.m. ET -, VALENCIA, Calif., Nov. ... financial results for the third quarter ended,September 30, 2007. ... expenses were $75.6,million, compared to $61.1 million for the ... was attributed to increased research,and development (R&D) expenses which ...
... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and marketer ... of its public offering of,4,898,398 shares of common stock ... by selling stockholders. Insulet will not receive any proceeds,from ... has granted to,the underwriters an option to purchase up ...
Cached Medicine News:Health News:HCA Reports Third Quarter 2007 Results 2Health News:HCA Reports Third Quarter 2007 Results 3Health News:HCA Reports Third Quarter 2007 Results 4Health News:HCA Reports Third Quarter 2007 Results 5Health News:HCA Reports Third Quarter 2007 Results 6Health News:HCA Reports Third Quarter 2007 Results 7Health News:HCA Reports Third Quarter 2007 Results 8Health News:HCA Reports Third Quarter 2007 Results 9Health News:HCA Reports Third Quarter 2007 Results 10Health News:HCA Reports Third Quarter 2007 Results 11Health News:HCA Reports Third Quarter 2007 Results 12Health News:HCA Reports Third Quarter 2007 Results 13Health News:HCA Reports Third Quarter 2007 Results 14Health News:RediClinic Announces Management Changes 2Health News:RediClinic Announces Management Changes 3Health News:Diabetes America Physicians Achieve Industry Recognition for Quality Patient Care 2Health News:AMDL Launches Expanded Distribution With 4th Round of Agreements Valued at $6.79 Million Annually for New Health & Beauty Product Line 2Health News:MannKind Corporation Reports Third Quarter Financial Results 2Health News:MannKind Corporation Reports Third Quarter Financial Results 3Health News:MannKind Corporation Reports Third Quarter Financial Results 4Health News:MannKind Corporation Reports Third Quarter Financial Results 5Health News:MannKind Corporation Reports Third Quarter Financial Results 6Health News:Insulet Corporation Announces Pricing of Secondary Public Offering 2
Tips are sharp on both sides to puncture, cut and tear the capsule...
...
...
... StressVue puts leading-edge stress testing within ... office or clinic to the most advanced ... vivid flat panel monitor with options for ... thermal printer for continuous printing. StressVue is ...
Medicine Products: